The PairX platform is based on a deep understanding of mRNA splicing biology, and it allows for the validation of tumor antigen-T Cell pairs in multiple patient-derived tumors. The company was founded by Prof. David Epstein and incubated by EVX Ventures, and its founding investors are EVX Ventures and Avendesora.